Marie Sébert

2.9k total citations
47 papers, 593 citations indexed

About

Marie Sébert is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Marie Sébert has authored 47 papers receiving a total of 593 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Hematology, 16 papers in Genetics and 14 papers in Molecular Biology. Recurrent topics in Marie Sébert's work include Acute Myeloid Leukemia Research (30 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers). Marie Sébert is often cited by papers focused on Acute Myeloid Leukemia Research (30 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (9 papers). Marie Sébert collaborates with scholars based in France, Italy and Germany. Marie Sébert's co-authors include Pierre Fenaux, Lionel Adès, Sylvain Thépot, Judith Michels, Joël S. Bloch, Roger Mouawad, Jean‐Philippe Spano, Guido Kroemer, David Khayat and Élodie Lainey and has published in prestigious journals such as Blood, PLoS ONE and Oncogene.

In The Last Decade

Marie Sébert

43 papers receiving 591 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marie Sébert France 13 313 281 123 116 62 47 593
Walid Rasheed Saudi Arabia 13 202 0.6× 359 1.3× 163 1.3× 69 0.6× 63 1.0× 49 608
Daniel H. Wiseman United Kingdom 15 337 1.1× 529 1.9× 96 0.8× 104 0.9× 60 1.0× 46 854
Yu Jing China 15 443 1.4× 301 1.1× 92 0.7× 127 1.1× 102 1.6× 74 667
Yoko Okitsu Japan 15 186 0.6× 320 1.1× 198 1.6× 110 0.9× 30 0.5× 49 647
Xielan Zhao China 14 244 0.8× 351 1.2× 116 0.9× 106 0.9× 29 0.5× 49 611
Catherine Godon France 11 307 1.0× 348 1.2× 192 1.6× 105 0.9× 24 0.4× 24 556
Amer M. Zeidan United States 7 493 1.6× 378 1.3× 160 1.3× 126 1.1× 95 1.5× 21 729
Jessica Boklan United States 12 134 0.4× 215 0.8× 118 1.0× 62 0.5× 52 0.8× 30 467
Yi-Cheng Wang United States 12 288 0.9× 276 1.0× 90 0.7× 55 0.5× 117 1.9× 15 517
Karsten Stahnke Germany 15 197 0.6× 327 1.2× 150 1.2× 76 0.7× 191 3.1× 23 635

Countries citing papers authored by Marie Sébert

Since Specialization
Citations

This map shows the geographic impact of Marie Sébert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marie Sébert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marie Sébert more than expected).

Fields of papers citing papers by Marie Sébert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marie Sébert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marie Sébert. The network helps show where Marie Sébert may publish in the future.

Co-authorship network of co-authors of Marie Sébert

This figure shows the co-authorship network connecting the top 25 collaborators of Marie Sébert. A scholar is included among the top collaborators of Marie Sébert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marie Sébert. Marie Sébert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhao, Lin‐Pierre, Emmanuelle Clappier, Matthieu Duchmann, et al.. (2025). Prognostic significance of monocytic-like phenotype in patients with AML treated with venetoclax and azacytidine. Blood Advances. 9(14). 3556–3565.
2.
Adès, Lionel, Thomas Cluzeau, Thibault Comont, et al.. (2024). Combining ESA and Luspatercept in Non-RS MDS Patients Having Failed ESA - Results of the Phase 1-2 Part a of the GFM Combola Study. Blood. 144(Supplement 1). 351–351. 3 indexed citations
3.
Lengliné, Étienne, Florence Rabian, Marco Cerrano, et al.. (2024). Blinatumomab consolidation for adult B-cell acute lymphoblastic leukemia in first and second complete remission. Blood Advances. 8(10). 2405–2409. 2 indexed citations
4.
5.
Cerrano, Marco, Sylvie Chevret, Emmanuel Raffoux, et al.. (2023). Benefits of dexamethasone on early outcomes in patients with acute myeloid leukemia with hyperleukocytosis: a propensity score matched analysis. Annals of Hematology. 102(4). 761–768. 6 indexed citations
6.
Sébert, Marie, et al.. (2023). Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes. Cancer Treatment Reviews. 123. 102673–102673. 5 indexed citations
7.
Sébert, Marie. (2023). Next-generation therapy for lower-risk MDS. Hematology. 2023(1). 59–64. 3 indexed citations
8.
Xhaard, Aliénor, Elsa Miekoutima, France Pirenne, et al.. (2022). The transfusion of non‐prophylactically RH‐KEL1 antigen‐matched red blood cells is feasible in selected myelodysplastic syndrome and acute myeloid leukaemia patients. Vox Sanguinis. 117(5). 693–700. 2 indexed citations
9.
Fodil, Sofiane, Sylvie Chevret, Sandrine Valade, et al.. (2022). Post-remission outcomes in AML patients with high hyperleukocytosis and inaugural life-threatening complications. PLoS ONE. 17(7). e0270744–e0270744. 2 indexed citations
10.
Zhao, Lin‐Pierre, Emmanuelle Clappier, Marie Sébert, et al.. (2021). Genomic landscape of MDS/CMML associated with systemic inflammatory and autoimmune disease. Leukemia. 35(9). 2720–2724. 25 indexed citations
11.
Kim, Rathana, Lin‐Pierre Zhao, Adèle de Masson, et al.. (2021). Clinical, pathological, and molecular features of myelodysplasia cutis. Blood. 139(8). 1251–1253. 19 indexed citations
12.
Raffoux, Emmanuel, Marie Robin, David Michonneau, et al.. (2021). Correction to: Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality. Leukemia. 35(3). 934–934. 6 indexed citations
13.
Duployez, Nicolas, Matthieu Duchmann, Laëtitia Largeaud, et al.. (2021). Prognostic Significance of DDX41 Germline Mutations in Intensively Treated AML Patients: An ALFA-Filo Study. Blood. 138(Supplement 1). 612–612.
14.
Raffoux, Emmanuel, Marie Robin, David Michonneau, et al.. (2020). Allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia or myelodysplastic syndromes: myth and reality. Leukemia. 35(1). 225–228. 7 indexed citations
15.
Ursu, Rénata, Jérôme LeGoff, Stéphanie Harel, et al.. (2020). 1721P Prolonged positive SARS-CoV-2 RT-PCR in cancer outpatients requires specific reorganization of cancer centres. Annals of Oncology. 31. S1010–S1010. 1 indexed citations
16.
Sébert, Marie, Marie Passet, Anna Raimbault, et al.. (2019). Germline DDX41 mutations define a significant entity within adult MDS/AML patients. Blood. 134(17). 1441–1444. 123 indexed citations
17.
18.
Lainey, Élodie, Marie Sébert, Sylvain Thépot, et al.. (2012). Erlotinib antagonizes ABC transporters in acute myeloid leukemia. Cell Cycle. 11(21). 4079–4092. 43 indexed citations
19.
Thépot, Sylvain, Élodie Lainey, Thomas Cluzeau, et al.. (2011). Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia. Cell Cycle. 10(14). 2323–2330. 43 indexed citations
20.
Thépot, Sylvain, Élodie Lainey, Marie Sébert, et al.. (2010). Hypomethylating Agents Correct Subcellular Localization of FOXO3a and (re)Establish Expression of Its Transcriptional Targets In AML and MDS- Cells. Blood. 116(21). 2173–2173. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Walid Rasheed Breakdown of academic impact, for papers by Daniel H. Wiseman Breakdown of academic impact, for papers by Yu Jing Breakdown of academic impact, for papers by Yoko Okitsu Breakdown of academic impact, for papers by Xielan Zhao Breakdown of academic impact, for papers by Catherine Godon Breakdown of academic impact, for papers by Amer M. Zeidan Breakdown of academic impact, for papers by Jessica Boklan Breakdown of academic impact, for papers by Yi-Cheng Wang Breakdown of academic impact, for papers by Karsten Stahnke
Rankless by CCL
2026